Rigel Pharmaceuticals Past Earnings Performance
Past criteria checks 3/6
Rigel Pharmaceuticals has been growing earnings at an average annual rate of 7.7%, while the Biotechs industry saw earnings growing at 19.1% annually. Revenues have been growing at an average rate of 7.1% per year.
Key information
7.7%
Earnings growth rate
8.5%
EPS growth rate
| Biotechs Industry Growth | 17.0% |
| Revenue growth rate | 7.1% |
| Return on equity | n/a |
| Net Margin | 2.5% |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Shares Could Be 36% Below Their Intrinsic Value Estimate
Nov 08
Rigel Pharma Remains Bullish, Growth Fueled By FDA-Approved Drugs, Strategic Partnerships
Oct 10Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Shares Fly 31% But Investors Aren't Buying For Growth
Sep 25There's No Escaping Rigel Pharmaceuticals, Inc.'s (NASDAQ:RIGL) Muted Revenues Despite A 29% Share Price Rise
Jul 30Rigel Pharmaceuticals: Undervalued FDA-Approved Products With Promising Cash Flow Potential
Jul 24Little Excitement Around Rigel Pharmaceuticals, Inc.'s (NASDAQ:RIGL) Revenues As Shares Take 29% Pounding
May 01Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates
Mar 08Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Surges 36% Yet Its Low P/S Is No Reason For Excitement
Mar 04Rigel Pharmaceuticals: Upgrading To A 'Top Idea' Ahead Of Promising Q4/2023 Earnings Report
Feb 23Lacklustre Performance Is Driving Rigel Pharmaceuticals, Inc.'s (NASDAQ:RIGL) Low P/S
Jan 15Is Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Trading At A 25% Discount?
Oct 25Rigel cutting 16% of workforce after declining to file sNDA for fostamatinib
Oct 10Rigel Pharma adds ~7% to reach over two month high
Aug 18Rigel rises 17% on strong Q2 result
Aug 03Rigel Pharmaceuticals: A Status Check
May 31Is Rigel Pharmaceuticals (NASDAQ:RIGL) A Risky Investment?
Apr 21Rigel Pharmaceuticals: Why The Stock Is On A Run
Mar 21Revenue & Expenses Breakdown
How Rigel Pharmaceuticals makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 157 | 4 | 110 | 0 |
| 30 Jun 24 | 130 | -14 | 108 | 0 |
| 31 Mar 24 | 119 | -20 | 106 | 0 |
| 31 Dec 23 | 116 | -25 | 106 | 0 |
| 30 Sep 23 | 129 | -24 | 111 | 0 |
| 30 Jun 23 | 121 | -38 | 112 | 0 |
| 31 Mar 23 | 125 | -45 | 113 | 0 |
| 31 Dec 22 | 116 | -59 | 112 | 0 |
| 30 Sep 22 | 86 | -83 | 105 | 0 |
| 30 Jun 22 | 87 | -85 | 102 | 0 |
| 31 Mar 22 | 77 | -85 | 97 | 0 |
| 31 Dec 21 | 139 | -18 | 92 | 0 |
| 30 Sep 21 | 138 | -15 | 89 | 0 |
| 30 Jun 21 | 136 | -8 | 84 | 0 |
| 31 Mar 21 | 131 | -11 | 80 | 0 |
| 31 Dec 20 | 109 | -30 | 77 | 0 |
| 30 Sep 20 | 106 | -28 | 73 | 0 |
| 30 Jun 20 | 108 | -25 | 74 | 0 |
| 31 Mar 20 | 102 | -28 | 73 | 0 |
| 31 Dec 19 | 59 | -67 | 75 | 0 |
| 30 Sep 19 | 82 | -46 | 78 | 0 |
| 30 Jun 19 | 66 | -59 | 78 | 0 |
| 31 Mar 19 | 57 | -64 | 76 | 0 |
| 31 Dec 18 | 45 | -70 | 70 | 0 |
| 30 Sep 18 | 7 | -100 | 63 | 0 |
| 30 Jun 18 | 3 | -93 | 53 | 0 |
| 31 Mar 18 | 1 | -87 | 44 | 0 |
| 31 Dec 17 | 4 | -78 | 38 | 0 |
| 30 Sep 17 | 7 | -68 | 30 | 0 |
| 30 Jun 17 | 10 | -73 | 27 | 0 |
| 31 Mar 17 | 19 | -67 | 24 | 0 |
| 31 Dec 16 | 20 | -69 | 21 | 0 |
| 30 Sep 16 | 26 | -66 | 18 | 0 |
| 30 Jun 16 | 35 | -50 | 18 | 0 |
| 31 Mar 16 | 32 | -51 | 18 | 0 |
| 31 Dec 15 | 29 | -51 | 18 | 0 |
| 30 Sep 15 | 29 | -61 | 20 | 0 |
| 30 Jun 15 | 16 | -75 | 20 | 0 |
| 31 Mar 15 | 10 | -87 | 22 | 0 |
| 31 Dec 14 | 8 | -91 | 23 | 0 |
| 30 Sep 14 | 6 | -85 | 20 | 0 |
| 30 Jun 14 | 6 | -88 | 20 | 0 |
| 31 Mar 14 | 7 | -86 | 20 | 0 |
| 31 Dec 13 | 7 | -89 | 20 | 0 |
Quality Earnings: RIGL has high quality earnings.
Growing Profit Margin: RIGL became profitable in the past.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: RIGL has become profitable over the past 5 years, growing earnings by 7.7% per year.
Accelerating Growth: RIGL has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.
Earnings vs Industry: RIGL has become profitable in the last year, making it difficult to compare its past year earnings growth to the Biotechs industry (16.6%).
Return on Equity
High ROE: RIGL's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.